CLAIM RECON INTEL

Pheochromocytoma

Q: What are the VA rating percentages for Pheochromocytoma?

Pheochromocytoma (DC 7918) is rated at 0% under 38 CFR § 4.119, DC 7918. Evaluate as malignant or benign neoplasm as appropriate. DC 7918 carries no fixed schedular percentage of its own. A benign pheochromocytoma (about 90 percent of cases) is evaluated as a benign neoplasm under DC 7915 (rate on residuals of endocrine dysfunction). A malignant pheochromocytoma is evaluated as a malignant neoplasm under DC 7914 (100 percent during active antineoplastic treatment, then rated on residuals).

Q: What rates 0% for Pheochromocytoma under 38 CFR § 4.119, DC 7918?

Under 38 CFR § 4.119, DC 7918 (DC 7918), a 0% rating for Pheochromocytoma requires: Evaluate as malignant or benign neoplasm as appropriate. DC 7918 carries no fixed schedular percentage of its own. A benign pheochromocytoma (about 90 percent of cases) is evaluated as a benign neoplasm under DC 7915 (rate on residuals of endocrine dysfunction). A malignant pheochromocytoma is evaluated as a malignant neoplasm under DC 7914 (100 percent during active antineoplastic treatment, then rated on residuals).

Q: What evidence do I need for a Pheochromocytoma VA claim?

Key evidence for a Pheochromocytoma claim includes: Recent lab results documenting the endocrine abnormality (for example, blood glucose/A1c, calcium, or hormone levels); Endocrinology records showing insulin/medication regimen, restricted diet, and any regulation of activities (diabetes); A dated log of crises and episodes, with ER/hospital records (for example, Addison's disease, diabetic ketoacidosis/hypoglycemia); Documentation of any separately compensable complications (neuropathy, retinopathy, kidney involvement); Confirmation that continuous medication is required for control. All evidence should document both the condition and its impact on daily functioning.

DC 791838 C.F.R. § 4.119

Diagnostic Code

DC 7918

38 C.F.R. § 4.119

Rating Range

0–0%

1 severity tier

Source

Referenced

38 C.F.R. Part 4

Pheochromocytoma is rated by the U.S. Department of Veterans Affairs under DC 7918 of 38 CFR § 4.119, DC 7918 across 1 severity tier (0%). Service connection requires (1) a current diagnosis, (2) an in-service event, injury, or exposure, and (3) a medical nexus opinion linking the two under 38 C.F.R. § 3.303.

Educational tool only. Not legal or medical advice. Not affiliated with the VA.

Overview

Rare tumor of the adrenal gland that produces excess adrenaline and noradrenaline, causing severe episodes of high blood pressure, rapid heart rate, headaches, and sweating.

Rating Criteria

Evaluate as malignant or benign neoplasm as appropriate. DC 7918 carries no fixed schedular percentage of its own. A benign pheochromocytoma (about 90 percent of cases) is evaluated as a benign neoplasm under DC 7915 (rate on residuals of endocrine dysfunction). A malignant pheochromocytoma is evaluated as a malignant neoplasm under DC 7914 (100 percent during active antineoplastic treatment, then rated on residuals).

Key Evidence

—Recent lab results documenting the endocrine abnormality (for example, blood glucose/A1c, calcium, or hormone levels)

—Endocrinology records showing insulin/medication regimen, restricted diet, and any regulation of activities (diabetes)

—A dated log of crises and episodes, with ER/hospital records (for example, Addison's disease, diabetic ketoacidosis/hypoglycemia)

—Documentation of any separately compensable complications (neuropathy, retinopathy, kidney involvement)

—Confirmation that continuous medication is required for control

—Complete list of prescribed endocrine medications and their side effects

C&P Exam Tips

1Endocrine ratings turn on objective findings - lab values, documented crises or episodes, and whether continuous medication is required (38 CFR 4.119). Bring your recent lab results.

2For diabetes mellitus (DC 7913), the rating builds on insulin injections, a restricted diet, and regulation of activities, then on episodes of ketoacidosis/hypoglycemia requiring hospitalizations or provider visits - document each one.

3Compensable complications of diabetes (such as neuropathy, retinopathy, or kidney involvement) are rated separately unless used to support a 100% evaluation - claim each complication.

4For adrenal conditions like Addison's disease, the rating counts crises and episodes per year (38 CFR 4.119) - keep a dated log; note that a crisis and an episode are defined differently.

5If your condition is controlled only by continuous medication, make sure that requirement is clearly stated on the exam record.

6Report your worst days, list all medications and side effects, and describe the effect on work and daily activity.

Tools

Rating Calculator →Secondaries Explorer →C&P Exam Prep →PACT Act Scanner →2026 Rates →

Sources & Editorial

Rating criteria reference 38 C.F.R. Part 4 (Schedule for Rating Disabilities). This entry has not yet undergone editorial review against the live regulation text — consult the authoritative source directly before relying on the criteria shown.

View 38 C.F.R. Part 4 on eCFR →Editorial Standards →Suggest a correction →

EDUCATIONAL TOOL ONLY. NOT LEGAL OR MEDICAL ADVICE.
NOT AFFILIATED WITH THE U.S. DEPARTMENT OF VETERANS AFFAIRS.
CLAIM RECON 2026

LOADING